* IRadimed Corp IRMD.OQ IRMD.O is expected to show a
rise in
quarterly revenue when it reports results on January 31
(estimated) for the period ending December 31 2023
* The Winter Springs Florida-based company is expected to
report
a 16.6% increase in revenue to $17.331 million from $14.86
million a year ago, according to the mean estimate from 3
analysts, based on LSEG data.The company's guidance on November
3 2023, for the period ended December 31, was for revenue
between $16.90 million and $17.40 million.
* LSEG's mean analyst estimate for IRadimed Corp is for
earnings
of 40 cents per share. The company's EPS guidance on November 3
2023, for the period ended December 31, was between $0.38 and
$0.41
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for IRadimed
Corp is
$58.00, above its last closing price of $43.12.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 0.36 0.36 0.43 Beat 18.4
Jun. 30 2023 0.30 0.31 0.36 Beat 16.1
Mar. 31 2023 0.28 0.28 0.30 Beat 5.9
Dec. 31 2022 0.30 0.30 0.32 Beat 6.7
Sep. 0.25 0.25 0.29 Beat 18.4
30 2022
Jun. 30 2022 0.24 0.24 0.26 Beat 10.6
Mar. 31 2022 0.21 0.21 0.22 Beat 7.3
Dec. 31 2021 0.21 0.21 0.33 Beat 57.1
This summary was machine generated January 29 at 14:04 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)